Company intelligence / Profile preview
Protheragen
New York, New York, United Statesprotheragen.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Protheragen has multiple antibody, CAR-T, gene therapy, and small molecule programs in its pipeline distributed across indications such as neoplasms, immune system diseases, cancer, and metabolic diseases. Notably, TT-173 (targeting tissue factor for wounds/injuries) and FHND-41 (targeting EGFR for non-small cell lung cancer) are in Phase 3; ROD-16 (targeting oxdC for hyperoxaluria) is in Phase 2. The company has additional programs at all development phases, including discovery and preclinical[2][8].
- Therapeutic areas
- DermatologyImmunologyOtherInfectious DiseasesNephrologyOncologyOphthalmology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateCAR-T cell therapyGene therapySmall moleculeNanobody therapy
- Industry
- Biotech
02
Drug pipeline
69 assets68 more assets in the full pipeline.
Beyond the preview
Go deeper on Protheragen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protheragen.